Not yet recruiting
Medical Nitrous Oxide Combined With Personalized Traumatic Script Exposure for the Treatment of Post-Traumatic Stress Disorder
NCT07927192· Phase 3· University Hospital, Tours· Source
Not yet recruiting
A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis
2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source
Not yet recruiting
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer
NCT07759492· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Not yet recruiting
A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)
2025-522648-42-01· Phase 2/3· Crinetics Pharmaceuticals Inc.· Source
Not yet recruiting
Evaluation of the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC)
NCT07007325· Early phase 1· Institut Cancerologie de l'Ouest· Source
Not yet recruiting
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
NCT07420439· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Recruiting
Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease
NCT07514338· Phase 2· Pharming Technologies B.V.· Source
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Prospective multicenter randomized controlled double-blind label study of the prophylaxis of recurrent pouchitis after fecal microbiota transplant in UC with ileo-anal anastomosis.
NCT03524352· Phase 3· Centre Hospitalier Universitaire De Nantes· Source
Recruiting
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
NCT07221188· Phase 3· GlaxoSmithKline· Source
Recruiting
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
NCT06656598· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Recruiting
IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as post transplantation maintenance therapy in patients with newly-diagnosed myeloma
2024-517325-43-00· Phase 2· Centre Hospitalier Universitaire De Nantes· Source
Active, not recruiting
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· Phase 3· Genmab· Source
Recruiting
MYELOFLUDATEP: Exploratory study evaluating the value of 18F-Fludarabine PET for the initial or relapsed assessment and therapeutic evaluation of patients with symptomatic multiple myeloma.
2024-515219-23-00· Phase 1· Centre Hospitalier Universitaire De Nantes· Source
Active, not recruiting
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC
2023-504753-12-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Active, not recruiting
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401· Phase 2· Avalyn Pharma Inc.· Source
Active, not recruiting
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure
NCT06045975· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
NCT05718323· Phase 2· ETOP IBCSG Partners Foundation· Source
Active, not recruiting
Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)
NCT05856695· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Completed
Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions
NCT05622071· Phase 2· UNICANCER· Source
Recruiting
Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets
NCT05627375· Phase 3· Centre Hospitalier Universitaire de Saint Etienne· Source
Recruiting
Aspirin for the Prevention of Preeclampsia and Pregnancy outcomes in nulliparous women after Assisted Reproductive Technology.
2022-500933-10-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source
Active, not recruiting
Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy
NCT05781308· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Active, not recruiting
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035· Phase 2· Merck Sharp & Dohme LLC· Source
Recruiting
Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
NCT05650229· Phase 2· Pharming Technologies B.V.· Source
Recruiting
Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia
NCT05338190· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Rusfertide in Adults With Polycythemia Vera (PV)
NCT05210790· Phase 3· Protagonist Therapeutics, Inc.· Source
Active, not recruiting
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
NCT04806451· Phase 3· Neurocrine Biosciences· Source
Active, not recruiting
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
NCT04621188· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Active, not recruiting
Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial
NCT04727307· Phase 2· University Hospital, Montpellier· Source
Recruiting
Statins for Venous Event Reduction in Patients With Venous Thromboembolism
NCT04319627· Phase 3· Ottawa Hospital Research Institute· Source
Active, not recruiting
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
NCT04490915· Phase 3· Neurocrine Biosciences· Source
Active, not recruiting
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)
NCT01817192· Phase 4· Razor Genomics· Source
Recruiting
Randomised Evaluation of COVID-19 Therapy
NCT04381936· Phase 3· University of Oxford· Source
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
NCT04221035· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Recruiting
Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
NCT03290456· Phase 3· Hospices Civils de Lyon· Source
Active, not recruiting
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
NCT03799835· Phase 3· UNICANCER· Source
Recruiting
Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole
NCT03656081· Phase 3· Poitiers University Hospital· Source
Active, not recruiting
Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients
NCT03643133· Phase 2· UNICANCER· Source
Active, not recruiting
Adjuvant immunotherapy after salvage surgery in head and neck squamous cell carcinoma: phase 2 trial evaluating the efficacy and the toxicity of nivolumab alone, and of the combination nivolumab and ipilimumab
2024-516810-39-00· Phase 2· Institut Gustave Roussy· Source